生物谷2月12日晚间发布业绩快报，2025年实现营业收入4.33亿元，同比下降16.12%；归属于上市公司股东的净利润为-5584.69万元，同比减亏24.94%。 报告期内，受行业政策调整、医疗卫生行业竞争加剧影响，公司核心集采产品灯盏生脉胶囊、灯盏细辛注射液销量增加，但各销售地区挂网价格出现不同 程度下调；公司核心产品销量同比增长较大，带动营业成本相应增加，产品毛利率较上期下降。 资料显示，生物谷是一家集灯盏花系列药品的研究、开发、生产、销售为一体的制药企业。公司于2020年7月27日在北交所上市。 上市第一年公司营收、净利润即双双下滑，第二年实现业绩增长，此后便陷入亏损泥潭。2022年至2024年，公司归母净利润分别为-4891.12万 元、-1220.03万元、-7440.10万元，加上2025年，已连续4年亏损。 上述被占用资金主要用于金沙江投资日常营运、归还债务、为金沙江投资控制的旅游项目提供资金等用途。 原审法院以背信损害上市公司利益罪判处被告人林艳和有期徒刑三年，并处罚金500万元；以背信损害上市公司利益罪判处被告人贺元有期徒刑一年六个 月，并处罚金200万元；冻结在案的6200万元发还生物谷 ...

每经记者｜王琳 每经编辑｜段炼 黄博文 并购重组 华培动力：拟购买美创智感100%股权 华培动力公告称，公司拟通过发行可转换公司债券及支付现金方式，购买无锡晟熠产业投资合伙企业（有限合伙）持有的美创智感（无锡）科技有限公司 （简称"美创智感"）100%股权，并向不超过35名特定投资者发行股份募集配套资金。本次交易预计构成关联交易，构成重大资产重组，但不构成重组上 市。公司A股股票自2月13日开市起停牌，预计停牌时间不超过10个交易日。 峆一药业：2025年归母净利润同比增长1.34% 峆一药业发布业绩快报称，公司预计2025年实现营业收入2.88亿元，同比增长6.37%；预计实现利润总额5387.92万元，同比增长0.77%；预计实现归母净 利润5033.19万元，同比增长1.34%。 厦门空港：拟以11.93亿元收购兆翔科技100%股权 厦门空港公告称，公司拟以现金方式收购公司控股股东厦门翔业集团有限公司的全资子公司厦门兆翔智能科技有限公司（简称"兆翔科技"）100%股权， 交易金额为11.93亿元。本次交易构成关联交易，但不构成重大资产重组。 中南文化：拟购买苏龙热电控股权 中南文化公告称，公司正在筹划通 ...

投资者是资本市场发展的根基。保护投资者特别是中小投资者的合法权益，是资本市场一切工作的出发 点和落脚点。业内人士表示，当前，我国多层次资本市场改革发展正不断深化，法治化、市场化进程持 续推进。展望未来，随着监管效能的持续提升和司法保障的日益强化，安全、规范、透明、开放、有活 力、有韧性的资本市场必将更好服务实体经济高质量发展，也让每一位投资者都能更安心分享上市公司 发展成果。 二审裁定生效后，执行法院快速将冻结资金发还生物谷，把判决书上的"白纸黑字"迅速转化为上市公司 账上的"真金白银"，对于协助生物谷惩首恶、追损失具有重要意义。目前，生物谷经营状况正常，并对 林艳和及相关主体提起民事诉讼，已被相关法院受理。资金占用案件带来的影响正在逐渐消除。 北交所上市公司生物谷近日公告称，公司资金占用案追款工作取得进展，被冻结在案的款项已全额发还 上市公司账户。从执行程序启动到资金划转至上市公司，全程历时不足一个月。 非经营性占用上市公司资金是严重损害上市公司利益和股东权益的违法行为。2021年8月至2022年3月， 生物谷创始人、前实际控制人林艳和安排时任公司董事会秘书兼财务总监贺元违反财务制度非经营性占 用生物谷资金 ...

投资者是资本市场发展的根基。保护投资者特别是中小投资者的合法权益，是资本市场一切工作的出发 点和落脚点。当前，我国多层次资本市场改革发展正不断深化，市场化、法治化、国际化进程持续推 进。展望未来，随着监管效能的持续提升和司法保障的日益强化，安全、规范、透明、开放、有活力、 有韧性的资本市场必将更好地服务于实体经济高质量发展，也让每一位投资者都能更安心地分享上市公 司发展成果。 （文章来源：证券日报） 本报讯 2月6日晚间，北交所上市公司云南生物谷药业股份有限公司（以下简称"生物谷"）发布公告 称，资金占用案追款工作取得进展，已收到原实控人冻结在案的款项。从执行程序启动到资金划转至上 市公司，全程历时不足一个月。 非经营性占用上市公司资金是严重损害上市公司利益和股东权益的违法行为。公告显示，2025年，经公 安机关侦办，检察院公诉和一审、二审法院审理，以背信损害上市公司利益罪判处生物谷原实控人、原 董秘兼财务总监二人有期徒刑并处罚金，判决将冻结在案的资金发还生物谷，并继续追缴违法所得退赔 生物谷。这不仅为挽回上市公司损失、保护投资者合法权益奠定了坚实基础，更有力维护了资本市场秩 序。 二审裁定生效后，执行法院快 ...

Market Overview - The A-share market showed mixed performance with the Shanghai Composite Index up by 0.11%, the Shenzhen Component Index up by 0.65%, and the ChiNext Index also up by 0.65% as of midday [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.38 trillion yuan, a decrease of 63.3 billion yuan compared to the previous trading day, with over 3,800 stocks rising [2] Sector Performance - Active sectors included lithium batteries, energy metals, humanoid robots, and fintech, while traditional sectors like liquor, retail, and AI application stocks weakened [1] - The Chinese medicine and chemical sectors showed notable gains, with the Chinese medicine sector rising by 2.52% [2][7] - The small metals sector rebounded, with stocks like Xianglu Tungsten and Zhangyuan Tungsten hitting the daily limit [7] Notable Stocks - Mingdiao Co. experienced significant trading activity, achieving a "limit-up" with nearly 700 million yuan in transactions and marking its fifth consecutive trading day of gains [3] - Jiangfeng Electronics saw a slight increase of 0.09% after announcing plans to acquire control of Kaide Quartz [9] Economic Indicators - The industrial development plan for traditional Chinese medicine aims for a collaborative development system by 2030, which may positively impact the sector [7]

Market Overview - A-shares showed resilience against external market pressures, with major indices recovering after a low opening, resulting in the Shanghai Composite Index rising by 4.40 points (0.11%) to 4080.31 points, the Shenzhen Component Index increasing by 90.46 points (0.65%) to 14043.17 points, and the ChiNext Index up by 21.17 points (0.65%) to 3281.45 points [1] Sector Performance - The chemical sector saw strong performance, with stocks like Cangzhou Dahua, Jinniu Chemical, Baichuan Co., and Baihehua hitting the daily limit [1] - The humanoid robot concept stocks were active, with companies such as Wuzhou Xinchun, Liancheng Precision, and Tianqi Co. also reaching the daily limit [1] - The non-ferrous metals sector showed signs of recovery, with Hunan Gold and Xianglu Tungsten hitting the daily limit [1] - The traditional Chinese medicine sector opened strong, with stocks like Te Yi Pharmaceutical reaching the daily limit [1] Policy Support - The Chinese government, through the Ministry of Industry and Information Technology and other departments, issued a development plan for the traditional Chinese medicine industry, aiming for a collaborative development system by 2030, which is expected to boost the sector's growth [2] Price Dynamics - The price of disperse dyes surged due to a significant increase in the cost of upstream key intermediates, rising from 25,000 yuan/ton to 38,000 yuan/ton, a more than 50% increase, which is expected to drive up prices in the textile dyeing industry as demand increases post-Spring Festival [3] Market Challenges - The liquor sector faced downward pressure, with stocks like Huangtai Liquor hitting the daily limit down, attributed to a decline in demand following the consumption peak around the Spring Festival and increased competition leading to price cuts [4] - AI application stocks experienced declines, with companies like Yaowang Technology and Zhejiang Wenhu falling to the daily limit due to concerns over technology maturity and unclear business models [5] - The optical module and CPO sectors continued to adjust, with stocks like Yuanjie Technology and Xinyisheng dropping over 6% as market expectations normalized [6] Institutional Insights - Zhongjin Securities noted that despite external pressures, there are no typical bull market top signals in Chinese stocks, with ample liquidity and improving earnings, suggesting a continued positive outlook for Chinese asset revaluation [7] - Tianfeng Securities highlighted the fragility of market sentiment, indicating that any news could trigger short-term sell-offs, particularly in the gold market [7] - Huachuang Securities observed a strong recovery in consumer markets expected for the 2026 Spring Festival, driven by government-led consumption initiatives, suggesting potential growth in sectors like dining, tourism, and retail [7]

Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Core Viewpoint - Lin Yanhe, the former chairman of Bio Valley, was sentenced to three years in prison for illegally transferring company funds to Shenzhen Jinsha River Investment Co., Ltd. The court rejected his request for probation [1][2]. Group 1: Legal Proceedings - Lin Yanhe was convicted of breaching trust and harming the interests of the listed company, receiving a three-year prison sentence and a fine of 5 million RMB. The former board secretary and financial director, He Yuan, was sentenced to 18 months in prison and fined 2 million RMB [2]. - The court ruled that the amount involved was particularly large and the social harm was severe, leading to the rejection of the defendants' requests for leniency based on self-reporting and contributions to damage control [2]. Group 2: Company Background - Bio Valley specializes in traditional Chinese medicine products, with its main products including Dan Zhan Sheng Mai capsules and Dan Zhan Xi Xin injections, which are used to treat ischemic cardiovascular and cerebrovascular diseases [2]. - The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [2]. Group 3: Financial Misconduct Details - From August 2021 to March 2022, Lin Yanhe arranged for He Yuan to transfer a total of 277 million RMB in non-operating funds to Jinsha River Investment under the guise of entrusted financial management, with 122 million RMB in 2021 and 155 million RMB in early 2022 [4]. - As of July 19, 2022, only 20 million RMB of the occupied funds had been returned, leaving 257 million RMB outstanding [4]. Group 4: Regulatory Actions - Lin Yanhe faced investigation by the China Securities Regulatory Commission (CSRC) in May 2022 for information disclosure violations and was publicly reprimanded by the Beijing Stock Exchange in July 2022 for fund occupation [3]. - He resigned as chairman in July 2022 and was banned from the securities market for life in September 2022 [3].

Group 1 - Huaxia Happiness's board rejected five temporary proposals from major shareholder Ping An Life, with a voting result of 1 in favor and 7 against [1] - The proposals were intended for discussion at the third temporary shareholders' meeting of Huaxia Happiness in 2025 [1] Group 2 - Bio Valley announced that its former actual controller and chairman Lin Yanhe was sentenced to three years in prison and fined 5 million yuan for breaching trust and harming the company's interests [2][5] - The court also sentenced former board secretary and financial director He Yuan to one and a half years in prison and fined 200,000 yuan [2] Group 3 - The People's Bank of China announced a one-time credit repair policy to support individuals with damaged credit who are actively repaying debts [7] - Individuals who repay overdue debts of up to 10,000 yuan by March 31, 2026, will have their overdue information not displayed in the financial credit information database [7] Group 4 - The Shanghai Municipal Science and Technology Commission announced a plan to support the research and development of new food technologies, including alternative proteins and 3D-printed foods, from 2026 to 2030 [14] - The initiative aims to meet diverse food consumption needs and promote sustainable development [14] Group 5 - Xiangyu Medical reported that its brain-computer interface products have entered over 500 top-tier hospitals, with plans to expand to 700 by the Spring Festival and 1,500 by next year [24] - The company anticipates rapid growth in sales revenue from these products in 2026 [24] Group 6 - Geely Automobile announced the completion of the privatization and merger of Zeekr Intelligent Technology, making it a wholly-owned subsidiary [23] - Zeekr has been delisted from the New York Stock Exchange following the merger [23] Group 7 - China Nuclear Engineering announced that its subsidiaries will introduce 5 billion yuan in investment through a non-public agreement to implement market-oriented debt-to-equity swaps [32] - The funds will be used to repay financial institution loans while maintaining actual control over the subsidiaries [32]

Core Points - Yunnan Biotech Pharmaceutical Co., Ltd. (referred to as "Biotech") announced that the Yunnan Provincial High People's Court upheld the original ruling, sentencing former actual controller Lin Yanhe to three years in prison and a fine of 5 million yuan, while former CFO He Yuan received a sentence of one and a half years and a fine of 2 million yuan [1] - The case involved Lin Yanhe and He Yuan misappropriating company funds for personal financial needs, leading to administrative penalties from the China Securities Regulatory Commission (CSRC) and subsequent criminal charges [1][2] - The CSRC has been actively enforcing strict regulations against financial misconduct, emphasizing the protection of small investors and the integrity of innovative small and medium-sized enterprises [2] Company Overview - Biotech was established in 1999 and focuses on the research, production, and sales of traditional Chinese medicine, specifically the "Dengzhanhua" system [1] - The company transitioned from the New Third Board to the Beijing Stock Exchange in 2021 [1] Legal Proceedings - The case against Lin Yanhe and He Yuan for breaching fiduciary duties was heard in Kunming Intermediate People's Court, resulting in a conviction and financial penalties, with the court ordering the return of misappropriated funds to Biotech [2] - The Yunnan Securities Regulatory Bureau initiated an investigation into the misconduct, leading to significant administrative penalties and a referral for criminal prosecution [1][2]